IL244260B - Insulating layer in a drug delivery compound, drug delivery compounds intended for sustained release and methods of making them - Google Patents

Insulating layer in a drug delivery compound, drug delivery compounds intended for sustained release and methods of making them

Info

Publication number
IL244260B
IL244260B IL244260A IL24426016A IL244260B IL 244260 B IL244260 B IL 244260B IL 244260 A IL244260 A IL 244260A IL 24426016 A IL24426016 A IL 24426016A IL 244260 B IL244260 B IL 244260B
Authority
IL
Israel
Prior art keywords
formulation
drug delivery
delayed drug
delivery formulation
preparing
Prior art date
Application number
IL244260A
Other languages
English (en)
Hebrew (he)
Other versions
IL244260A0 (en
Inventor
Jose Oliveira Varum Felipe
Carlos Bravo Gonzalez Roberto
Buser Thomas
Waseh Basit Abdul
Cristina Freire Ana
Original Assignee
Tillotts Pharma Ag
Jose Oliveira Varum Felipe
Carlos Bravo Gonzalez Roberto
Buser Thomas
Waseh Basit Abdul
Cristina Freire Ana
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tillotts Pharma Ag, Jose Oliveira Varum Felipe, Carlos Bravo Gonzalez Roberto, Buser Thomas, Waseh Basit Abdul, Cristina Freire Ana filed Critical Tillotts Pharma Ag
Publication of IL244260A0 publication Critical patent/IL244260A0/en
Publication of IL244260B publication Critical patent/IL244260B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846Poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/005Coating of tablets or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/60Salicylic acid; Derivatives thereof
    • A61K31/606Salicylic acid; Derivatives thereof having amino groups
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893Tablet coating processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10Laxatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL244260A 2013-10-29 2016-02-23 Insulating layer in a drug delivery compound, drug delivery compounds intended for sustained release and methods of making them IL244260B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2013/072648 WO2015062640A1 (en) 2013-10-29 2013-10-29 A delayed release drug formulation

Publications (2)

Publication Number Publication Date
IL244260A0 IL244260A0 (en) 2016-04-21
IL244260B true IL244260B (en) 2021-08-31

Family

ID=49515360

Family Applications (2)

Application Number Title Priority Date Filing Date
IL244260A IL244260B (en) 2013-10-29 2016-02-23 Insulating layer in a drug delivery compound, drug delivery compounds intended for sustained release and methods of making them
IL265381A IL265381B (en) 2013-10-29 2019-03-14 Insulating layer in a drug delivery compound, drug delivery compounds designed for sustained release and methods of making them

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL265381A IL265381B (en) 2013-10-29 2019-03-14 Insulating layer in a drug delivery compound, drug delivery compounds designed for sustained release and methods of making them

Country Status (25)

Country Link
US (1) US10799515B2 (enExample)
EP (2) EP3542791A1 (enExample)
JP (1) JP6273356B2 (enExample)
KR (2) KR102174942B1 (enExample)
CN (2) CN105555260B (enExample)
AU (2) AU2013404367B2 (enExample)
BR (2) BR122020013726B1 (enExample)
CA (1) CA2923063C (enExample)
CR (1) CR20160192A (enExample)
CU (1) CU20160055A7 (enExample)
EA (1) EA032504B1 (enExample)
HK (1) HK1222547A1 (enExample)
IL (2) IL244260B (enExample)
MA (1) MA38847B2 (enExample)
MX (2) MX388063B (enExample)
MY (1) MY189394A (enExample)
NZ (2) NZ747731A (enExample)
PH (2) PH12020551522A1 (enExample)
SA (2) SA116370660B1 (enExample)
SG (1) SG11201600501UA (enExample)
TN (1) TN2016000119A1 (enExample)
TW (3) TWI736031B (enExample)
UA (1) UA117260C2 (enExample)
WO (1) WO2015062640A1 (enExample)
ZA (1) ZA201600630B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20200144A1 (ar) 2012-04-30 2017-06-16 Tillotts Pharma Ag تركيبة عقار ذو إطلاق متأخر
CN113061089A (zh) 2015-09-23 2021-07-02 凯瑞康宁生物工程(武汉)有限公司 γ-羟基丁酸的前药及其组合物和用途
EP3162362A1 (de) 2015-10-30 2017-05-03 Dr. Falk Pharma Gmbh Optimierte mesalazinhaltige hochdosistablette
EP3257501A1 (en) 2016-06-14 2017-12-20 Tillotts Pharma AG Multiple unit dosage form comprising a core with individual core units covered by a mucoadhesive material, and an enteric core coating
US20190193928A1 (en) * 2017-12-21 2019-06-27 Pepsico, Inc. Multi-ingredient ephemeral beverage pod for making a beverage
EP3662898A1 (en) * 2018-12-07 2020-06-10 Tillotts Pharma AG Solid composition comprising mesalazine
EP3662902B1 (en) * 2018-12-07 2024-07-31 Tillotts Pharma AG Colonic drug delivery formulation
EP3662895A1 (en) 2018-12-07 2020-06-10 Tillotts Pharma AG A process for manufacturing reducing sugar-free 5-asa tablet cores
EP3662901B1 (en) 2018-12-07 2025-01-01 Tillotts Pharma AG Delayed release drug formulation comprising an outerlayer with an enzymatically degradable polymer, its composition and its method of manufacturing
EP3662900A1 (en) * 2018-12-07 2020-06-10 Tillotts Pharma AG Colonic drug delivery formulation
GB201906917D0 (en) * 2019-05-16 2019-07-03 Intract Pharma Ltd Novel compositions
JP7624444B2 (ja) * 2019-12-11 2025-01-30 エボニック オペレーションズ ゲーエムベーハー 病気の治療又は予防において使用するための剤形

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8812490D0 (en) 1988-05-26 1988-06-29 Agricultural & Food Res Delayed release formulations
GB8819110D0 (en) 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
IT1230576B (it) * 1988-10-20 1991-10-28 Angeli Inst Spa Formulazioni farmaceutiche per via orale a liberazione selettiva nel colon
SE8903914D0 (sv) 1989-11-22 1989-11-22 Draco Ab Oral composition for the treatment of inflammatory bowel diseases
GB8926639D0 (en) 1989-11-24 1990-01-17 Agricultural & Food Res Delayed release formulations
US5422121A (en) 1990-11-14 1995-06-06 Rohm Gmbh Oral dosage unit form
US5914132A (en) * 1993-02-26 1999-06-22 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
US5656290A (en) 1993-02-26 1997-08-12 The Procter & Gamble Company Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
FR2711525B1 (fr) * 1993-10-29 1996-01-12 Virbac Laboratoires Forme Galénique à administration orale pour animaux, son procédé de préparation et ses applications.
US5508276A (en) 1994-07-18 1996-04-16 Eli Lilly And Company Duloxetine enteric pellets
CA2236605A1 (en) 1997-05-09 1998-11-09 Yves Duccini Scale inhibitors
GB9722426D0 (en) 1997-10-23 1997-12-24 Univ London Pharmacy Controlled release formulations
GB9724186D0 (en) 1997-11-14 1998-01-14 British Tech Group Low temperature coatings
US6365185B1 (en) 1998-03-26 2002-04-02 University Of Cincinnati Self-destructing, controlled release peroral drug delivery system
EP1108431B1 (en) 1999-12-16 2003-05-02 Laboratorio Medinfar-Produtos Farmaceuticos, S.A. Gastroresistant multi-unitary pharmaceutical preparations containing piroxicam
DE10013029A1 (de) * 2000-03-17 2001-09-20 Roehm Gmbh Mehrschichtige Arzneiform für die Colonfreigabe
FI20000780L (fi) 2000-04-03 2001-10-04 Novasso Oy Peroraalinen lääkemuoto lääkeaineen hallituksi vapauttamiseksi
GB2367002A (en) 2000-09-25 2002-03-27 British Sugar Plc Coating composition
US20030035839A1 (en) 2001-05-15 2003-02-20 Peirce Management, Llc Pharmaceutical composition for both intraoral and oral administration
EP1391200A4 (en) * 2001-05-25 2004-06-16 Ssp Co Ltd DRUG
US7183321B2 (en) * 2001-12-17 2007-02-27 Bristol-Myers Squibb Company Antidiabetic formulation and method
GB0203421D0 (en) 2002-02-13 2002-04-03 Alizyme Therapeutics Ltd Composition
US20040028737A1 (en) 2002-08-12 2004-02-12 Kopran Research Laboratories Limited Enteric coated stable oral pharmaceutical composition of acid unstable drug and process for preparing the same
JP2006515318A (ja) 2002-10-29 2006-05-25 ファルマシア・コーポレーション 特異的に発現する癌関連遺伝子、それによってコードされるポリペプチドおよびその使用方法
US7670627B2 (en) 2002-12-09 2010-03-02 Salvona Ip Llc pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients
WO2004058228A1 (en) 2002-12-24 2004-07-15 Lupin Limited Enteric coated fluoxetine composition
GB0403247D0 (en) 2004-02-13 2004-03-17 Tillotts Pharma Ag A pharmaceutical composition
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
WO2007034503A2 (en) 2005-06-20 2007-03-29 Cadila Healthcare Limited Controlled release dosage formulation of duloxetine
DE102005032806A1 (de) * 2005-07-12 2007-01-18 Röhm Gmbh Verwendung eines teilneutralisierten, anionischen (Meth)acrylat-Copolymers als Überzug für die Herstellung einer Arzneiform mit einer Wirkstofffreisetzung bei erniedrigten pH-Werten
GB0607534D0 (en) 2006-04-13 2006-05-24 Univ London Pharmacy Colonic drug delivery formulation
WO2008020286A2 (en) * 2006-08-14 2008-02-21 Torrent Pharmaceuticals Limited Pharmaceutical compositions of duloxetine
TW200843802A (en) 2007-02-09 2008-11-16 Drugtech Corp Compositions for improving gastrointestinal nutrient and drug absorption
JP2008214249A (ja) * 2007-03-02 2008-09-18 Takeda Chem Ind Ltd 製剤における溶出改善方法および溶出性の改善された製剤
EP2143424A4 (en) 2007-03-26 2013-07-31 Teikoku Seiyaku Kk ORAL PHARMACEUTICAL PREPARATION FOR SPECIFIC DELIVERY TO THE COLON
KR101443943B1 (ko) * 2007-05-07 2014-10-07 에보니크 룀 게엠베하 가속된 약물 방출을 갖는 장용 코팅을 포함하는 고체 투여 형태
US20090162434A1 (en) * 2007-12-21 2009-06-25 Disphar International Bv Mesalazine tablet
GB0808537D0 (en) 2008-05-12 2008-06-18 Archimedes Dev Ltd Compositions
US20110177164A1 (en) 2008-10-06 2011-07-21 Gopal Rajan Pharmaceutical Compositions Comprising Amorphous Esomeprazole, Dosage Forms And Process Thereof
KR102012111B1 (ko) 2009-06-15 2019-08-19 아마린 파마, 인크. 병용 스타틴 요법을 받는 대상체에서 ldl-c 수준을 상승시키지 않으면서 트리글리세리드를 저하시키기 위한 조성물 및 방법
DE102009033621A1 (de) 2009-07-17 2011-01-20 Add Technologies Ltd. Trennschichten für pharmazeutische Zubereitungen zur Verhinderung von Wechselwirkungen zwischen Arzneistoffen und pharmazeutisch-technologischen Hilfsstoffen
JP5827952B2 (ja) 2009-10-09 2015-12-02 ユンジン・ファーム・カンパニー・リミテッドYungjin Pharm. Co. Ltd. 速効性と持続性を同時に有する薬剤学的組成物
EP2384746A3 (en) * 2010-05-05 2012-03-07 Sanovel Ilac Sanayi ve Ticaret A.S. Dual release oral tablet compositions of dexlansoprazole
US20130259947A1 (en) 2010-11-29 2013-10-03 Dr. Reddy's Laboratories Ltd. Oral metronidazole pharmaceutical compositions
WO2013035081A2 (de) 2011-09-07 2013-03-14 JÄNISCH, Melisa Optimale formulierung zur freisetzung eines wirkstoffes im dickdarm
CN102319218B (zh) 2011-09-22 2014-10-01 贝沃特医药技术(上海)有限公司 一种治疗肠道疾病的药物缓控释微粒制剂及其制备方法
JOP20200144A1 (ar) 2012-04-30 2017-06-16 Tillotts Pharma Ag تركيبة عقار ذو إطلاق متأخر
US9844436B2 (en) 2012-10-26 2017-12-19 Edwards Lifesciences Corporation Aortic valve and conduit graft implant tool

Also Published As

Publication number Publication date
SA114360006B1 (ar) 2016-11-09
HK1222547A1 (zh) 2017-07-07
KR20160077040A (ko) 2016-07-01
BR112016004863A8 (pt) 2020-02-11
MX388063B (es) 2025-03-19
AU2013404367A1 (en) 2016-02-18
MX2016001840A (es) 2016-08-11
TN2016000119A1 (en) 2017-10-06
PH12016500307B1 (en) 2022-02-11
BR122020013726B1 (pt) 2022-11-01
TW202011945A (zh) 2020-04-01
NZ747731A (en) 2020-02-28
AU2013404367B2 (en) 2020-02-27
TWI680774B (zh) 2020-01-01
TW201542243A (zh) 2015-11-16
PH12020551522A1 (en) 2022-11-14
JP2016535030A (ja) 2016-11-10
EA032504B1 (ru) 2019-06-28
US20160250232A1 (en) 2016-09-01
CU20160055A7 (es) 2016-10-28
JP6273356B2 (ja) 2018-01-31
CN110279669B (zh) 2022-02-15
PH12016500307A1 (en) 2016-05-16
TW201944984A (zh) 2019-12-01
SA116370660B1 (ar) 2019-02-24
MA38847B2 (fr) 2021-02-26
AU2020201365B2 (en) 2021-09-16
NZ717159A (en) 2019-06-28
IL244260A0 (en) 2016-04-21
EP3062776A1 (en) 2016-09-07
CN105555260B (zh) 2021-04-23
MX382146B (es) 2025-03-13
BR112016004863B1 (pt) 2022-09-20
SG11201600501UA (en) 2016-02-26
TWI736031B (zh) 2021-08-11
ZA201600630B (en) 2017-05-31
KR102174942B1 (ko) 2020-11-06
IL265381B (en) 2022-05-01
MA38847A1 (fr) 2017-08-31
KR20200075041A (ko) 2020-06-25
MY189394A (en) 2022-02-09
CN105555260A (zh) 2016-05-04
CR20160192A (es) 2016-07-13
TWI725458B (zh) 2021-04-21
UA117260C2 (uk) 2018-07-10
AU2020201365A1 (en) 2020-03-12
EP3542791A1 (en) 2019-09-25
EA201690596A1 (ru) 2016-08-31
US10799515B2 (en) 2020-10-13
CA2923063A1 (en) 2015-05-07
MX2019002162A (es) 2019-06-17
IL265381A (en) 2019-05-30
CA2923063C (en) 2021-09-07
WO2015062640A1 (en) 2015-05-07
CN110279669A (zh) 2019-09-27
KR102237356B1 (ko) 2021-04-08

Similar Documents

Publication Publication Date Title
IL265381B (en) Insulating layer in a drug delivery compound, drug delivery compounds designed for sustained release and methods of making them
IL240849A0 (en) Drug delivery devices and drug delivery method
GB201319681D0 (en) System and method for drug delivery
ZA201600720B (en) Beverage preparation system and method for preparing a beverage
PT3375333T (pt) Sistema de preparação de bebida
GB201308929D0 (en) A beverage preparation system, a capsule and a method for forming a beverage
PT2996966T (pt) Sistema de preparação de bebidas, cápsula e método para a formação de uma bebida
EP3082419A4 (en) Drug mixing and delivery system and method
IL240551A0 (en) Capsule, system and method for making a beverage
EP3003454A4 (en) Apparatus and methods for drug delivery using multiple reservoirs
EP3064174A4 (en) Device and method for loading implant into delivery system
EP3272387A4 (en) Drug administration device, and manufacturing method for drug administration device
EP3056521A4 (en) Super-absorbent resin and method for preparing same
IL245445A0 (en) Devices, kits and methods for osmotic administration of drugs
EP2990512A4 (en) Wrapping net, and manufacturing method for same
EP3031832A4 (en) Method for preparing polyolefin and polyolefin prepared thereby
IL243605A0 (en) Metallo-organic materials and a method for their preparation
EP2964289A4 (en) DEVICE, SYSTEM AND METHOD OF SUBCUTANEOUS DRUG DELIVERY
ZA201700285B (en) Ganirelix precursor and method for preparing ganirelix acetate by using ganirelix precursor
EP2968884A4 (en) DEVICE AND METHOD FOR DISPENSING MEDICAMENTS
EP3088023A4 (en) Drug administration device and method for controlling drug administration device
EP3027122A4 (en) Anchor delivery system and method
EP3053558A4 (en) Stretchable structure for absorbent article, absorbent article comprising said stretchable structure, and method for forming stretchable structure for absorbent article
EP3001465A4 (en) Light-emitting element and method for preparing same
GB201321398D0 (en) An apparatus and method for providing aerosolized powder delivery